Cover Image

In vivo suppression of HIV rebound by didehydro-Cortistatin A, a 'block-and-lock' strategy for HIV-1 cure

Saved in:

Bibliographic Details
Main Authors:	C.F. Kessing (Author), C.C. Nixon (Author), C. Li (Author), P.M. Tsai (Author), H. Takata (Author), G. Mousseau (Author), P.T. Ho (Author), J.B. Honeycutt (Author), M. Fallahi (Author), L. Trautmann (Author), J.V. Garcia (Author), S.T. Valente (Author)
Format:	Book
Published:	Elsevier, 2017-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tat inhibition by didehydro-cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat
by: C. Li, et al.
Published: (2019)

Molecular characterisation of the inhibitor didehydro-Cortistatin A with the HIV-1 Tat protein
by: S. Mediouni, et al.
Published: (2017)

Resistance to the Tat inhibitor didehydro-cortistatin A is mediated by heightened basal HIV-1 transcription
by: S. Mediouni, et al.
Published: (2019)

Suppression of the HIV-1 reservoir with a potent Tat inhibitor
by: S. Valente, et al.
Published: (2015)

Cycle ergometer and rebound exercises with chest physiotherapy - a useful adjunct for sputum expectoration in mild to moderately symptomatic hiv infected children.
by: S.S. Maharaj, et al.
Published: (2008)

Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint
by: M. Abdel-Mohsen, et al.
Published: (2019)

Effect of natural killer cells on viral rebound in HIV-1-infected humanized mice
by: J. Kim, et al.
Published: (2019)

The Neuropeptide Cortistatin Alleviates Neuropathic Pain in Experimental Models of Peripheral Nerve Injury
by: Clara P. Falo, et al.
Published: (2021)

11 Murine model to predict viral rebound in HIV+ allotransplanted subjects
by: Maria Salgado, et al.
Published: (2017)

Therapeutic Effect of a Latent Form of Cortistatin in Experimental Inflammatory and Fibrotic Disorders
by: Jenny Campos-Salinas, et al.
Published: (2022)

Chest physiotherapy and rebound exercise for sputum in patients co-infected with TB and HIV
by: S. Maharaj, et al.
Published: (2014)

PP 1.13 - 00078 CTL epitopes from structurally important hiv proteins are identified in rebound HIV
by: E. Lee, et al.
Published: (2022)

PP 4.11 - 00126 Autologous Neutralizing Antibodies Increase with Early Antiretroviral Therapy and Shape HIV Rebound after Treatment Interruption
by: E. Esmaeilzadeh, et al.
Published: (2022)

Marked variation in the susceptibility of HIV-1 to type 1 interferon inhibition during early, late and rebound infection
by: M. Gondim, et al.
Published: (2019)

PP 7.10 - 00088 Macrophage-Tropic HIV-1 Variants Contribute to Pediatric Rebound Viremia off ART
by: K. Ganta, et al.
Published: (2022)

Rate of HIV rebound and CD4 T cell kinetics in an ageing population on successful antiretroviral therapy
by: Abhishek Katiyar, et al.
Published: (2018)

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption
by: You Park, et al.
Published: (2017)

Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection
by: Defu Yuan, et al.
Published: (2023)

PP 4.10 - 00119 Multiomic dynamics of the cellular HIV reservoir after rebound during ATI
by: V. Wu, et al.
Published: (2022)

Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV
by: A.L. Hill, et al.
Published: (2015)

PP 7.9 - 00073 HIV-1 Cell-Associated RNA Provides 0.8 Prediction Accuracy for Time to Rebound after Treatment Interruption
by: Janet Huie, et al.
Published: (2022)

OP 4.4 - 00018 HIV reservoir burden associates with numbers of HIV-specific CD8+ T cells under long-term antiretroviral therapy and prevents them from differentiating into functional memory cells
by: H. Takata, et al.
Published: (2022)

PP 1.10 - 00069 Isotretinoin enhances IL-15 mediated HIV latency reversal and reduces the inducible latent reservoir
by: J. Howard, et al.
Published: (2022)

29 In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels, and latent HIV infection
by: P. Tsai, et al.
Published: (2016)

Fingolimod treatment at ART initiation delays SIV rebound after ART interruption
by: M. Pino, et al.
Published: (2019)

Conditions for post-rebound SHIV control in autologous hematopoietic-stem cell transplantation
by: F. Cardozo, et al.
Published: (2019)

Barcoded viruses facilitate tracking changes to the composition of the rebound-competent reservoir
by: B. Keele, et al.
Published: (2019)

Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine significantly reduces levels of HIV RNA and HIV DNA rebound following ART interruption in a phase I/II randomized controlled clinical trial
by: Erwann P. Loret, et al.
Published: (2016)

Rudimentary Treatise on the Construction of Locks
by: Dodd, George, 1808-1881; Hobbs, A. C., 1812-1891; Tomlinson, Charles, 1808-1897 [Editor]

Locke
by: Fowler, Thomas, 1832-1904

PP 2.12 - 00153 eCD4-Ig-DNA Decreased HIV Reservoir and Delayed Viral Rebound Through Fc Mediated Functions in BLT Humanized Mice
by: Z. Yuan, et al.
Published: (2022)

α4β7-blockade delays viral rebound in SHIV infected macaques treated with a combination of HIV bNAbs
by: E. Martinelli
Published: (2019)

HIV persistence: to the periphery and beyond
by: J.V. Garcia Martinez
Published: (2015)

Early adiposity rebound: predictors and outcomes
by: Alessandra Li Pomi, et al.
Published: (2024)

Rebound pain: Undesired, yet unexplored
by: Pradeep Bhatia, et al.
Published: (2022)

30,000 Locked Out: The Great Strike of the Building Trades in Chicago
by: Beeks, James C.

Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing
by: Chantelle Ahlenstiel, et al.
Published: (2015)

Littlebourne Lock
by: Harrison, F. Bayford

The Mystery of the Locks
by: Howe, E. W. (Edgar Watson), 1853-1937

Curly Locks
by: Anonymous